This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bryant, S. R. Articles by Lindner, V. Search for Related Content PubMed PubMed Citation Articles by Bryant, S. R. Articles by Lindner, V. Related Collections Animal models of human disease Growth factors/cytokines Quantitative modeling

(Circulation Research. 1999;84:323-328.)
© 1999 American Heart Association, Inc.

Original Contribution

Vascular Remodeling in Response to Altered Blood Flow Is Mediated by Fibroblast Growth Factor-2

Shane R. Bryant, Robert J. Bjercke, David A. Erichsen, Ajay Rege, Volkhard Lindner

From the Center for Molecular Medicine (S.R.B., V.L.), Maine Medical Center Research Institute, South Portland, Maine; Texas Biotechnology Corporation (R.J.B., D.A.E., A.R.), Houston, Tex.

Correspondence to Volkhard Lindner, MD, PhD, Center for Molecular Medicine, Maine Medical Center Research Institute, 125 John Roberts Rd, Suite 12, South Portland, ME 04106. E-mail lindnv{at}poa.mmc.org

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Abstract—Vascular structures adapt to changes in blood flow by adjusting their diameter accordingly. The factors mediating this process are only beginning to be identified. We have recently established a mouse model of arterial remodeling in which flow in the common carotid artery is interrupted by ligation of the vessel near the carotid bifurcation, resulting in a dramatic reduction in vessel diameter as a consequence of inward remodeling and intimal lesion formation. In the present study, we used this model to determine the role of fibroblast growth factor-2 (FGF-2) in the remodeling response by maintaining neutralizing serum levels of a mouse monoclonal antibody against FGF-2 for 4 weeks. Morphometric analysis revealed that intimal lesion formation was not affected by the antibody. However, lumen narrowing was significantly inhibited, resulting in a greater than 3-fold increase in lumen area in anti–FGF-2–treated animals compared with controls. Treatment with anti–FGF-2 antibody significantly inhibited the reduction in vessel diameter (inward remodeling) and shortening of the internal elastic lamina in the ligated vessel. In addition, anti–FGF-2 treatment also caused outward remodeling of the contralateral carotid artery. These findings identify FGF-2 as an important factor in vascular remodeling, and its effects are likely to be mediated by increasing vascular tone. The results are consistent with the recent observation of reduced vascular tone in the FGF-2–deficient mouse.

Key Words: basic fibroblast growth factor • fibroblast growth factor-2 • intima • smooth muscle

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Vascular remodeling is a well-described response of blood vessels to both physiological and pathological stimuli, leading to either vessel enlargement (positive or outward remodeling) or reduction (negative or inward remodeling). Examples of increased flow and/or lumen enlargement have been described in fetal development¹ and in clinical situations after graft placement^{2 3 4 5} or angioplasty.^{6 7 8} All studies found that neointimal proliferation or intimal area after angioplasty showed little correlation with restenosis (measured by lumen area) because of permanent changes in vascular geometry. In humans, intravascular ultrasound has failed to show a correlation between lumen area (percentage of stenosis) and neointima area,^{9 10} and vascular remodeling, as measured by a decrease in vessel area, was shown to account for the majority of the restenosis process.

Two important mechanisms by which hemodynamic forces may participate in remodeling are by regulation of endothelial cell function and matrix composition and organization within the vessel. Fluid flow is a prominent mediator of endothelial cell structure and function.^{11 12} Endothelial cell responses stimulated by flow participate in vessel development,¹³ remodeling,¹⁴ tone,¹⁵ and atherosclerosis.¹⁶ Flow alters endothelial cell properties such as orientation in the vessel wall,¹⁷ distribution of cytoskeletal elements,^{17 18} and expression of genes, including platelet-derived growth factor (PDGF) A and B chains,^{19 20 21} as well as release of endothelial-derived relaxing factor.²²

Studies by Guyton and Hartley²³ and Langille and O'Donnell¹⁴ established ligation of rat and rabbit carotid arteries, respectively, as useful models of flow-dependent remodeling. In these models, flow was decreased in one carotid artery and over 4 to 12 weeks, the vessel diameter decreased in the flow-restricted vessel and increased in the contralateral flow-augmented vessel. In addition, Langille²⁴ assessed the role of the endothelium by either gently denuding endothelium or gently disrupting endothelial membranes. Both procedures totally prevented alterations in vessel diameter. Thus, it appears that the endothelium is a critical mediator of the flow-dependent remodeling response.

We have recently established and characterized a mouse model of arterial remodeling.²⁵ In this model, flow in the common carotid artery is interrupted by ligation of the vessel near the carotid bifurcation, resulting in a dramatic reduction in vessel diameter and formation of an intimal lesion. Neointima formation and the influx of inflammatory cells in this model are markedly reduced in P-selectin–deficient mice, while the reduction in vessel diameter is not affected by the lack of P-selectin.²⁶ Additional specific factors that mediate the remodeling response are beginning to emerge. Several studies have implicated nitric oxide (NO) as an inhibitor of remodeling events.^{27 28 29 30} Using a mouse model, Rudic et al³¹ recently reported that endothelial-derived NO is involved in this process. The authors reported that ligation of the external carotid artery in endothelial nitric oxide synthase (eNOS)–deficient mice caused thickening of the wall of the ipsilateral common carotid artery accompanied by a hyperplastic response of the vessel. This response was not seen in wild-type control mice. Our studies demonstrated that alterations in blood flow also lead to changes in gene expression of growth factors that are known to modulate proliferation and migration^{32 33 34 35} of smooth muscle cells (SMCs).³⁶ Using en face techniques, we demonstrated that a 90% reduction in flow in the rat carotid artery caused a dramatic increase in PDGF-A and PDGF-B mRNA expression in the endothelium of the carotid artery with reduced flow. No change in expression of these genes was seen in the endothelium of the contralateral carotid artery that is expected to experience a compensatory increase in flow. Fibroblast growth factor-2 (FGF-2), which is known to mediate diverse biological effects including angiogenesis, bone formation, mitogenesis, migration, wound healing, neuronal survival, tumor growth,^{37 38} as well as vascular lesion formation in injured arteries,³⁹ has very recently been identified as a crucial factor in the regulation of vascular tone.⁴⁰ Zhou et al⁴⁰ demonstrated that FGF-2–deficient mice display low blood pressure and decreased vascular contractility. Interestingly, like wild-type mice, these FGF-2–deficient mice exhibited a normal hyperplastic reaction in response to a denuding vascular injury. To examine the role of FGF-2 in vascular remodeling, the present study used the carotid artery ligation model in mice in which circulating levels of a neutralizing mouse monoclonal antibody against FGF-2 or a control antibody were maintained for 4 weeks. Morphometric analysis revealed that treatment with the FGF-2 antibody significantly inhibited lumen narrowing and negative remodeling while neointima formation was not affected by the antibody. These findings demonstrate that FGF-2 plays an important role in vascular remodeling.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Animals
All animal studies were approved by the Institutional Animal Care and Use Committee. Twenty female FVB mice (3 to 4 months old, Jackson Laboratories, Bar Harbor, Maine) weighing 25 to 30 g were used in all experiments. The animals were anesthetized by intraperitoneal injection with a solution of xylazine (5 mg/kg, AnaSed, Lloyd Laboratories, Shenandoah, Iowa) and ketamine (80 mg/kg body weight, Ketaset, Aveco Co, Inc, Fort Dodge, Iowa). The left common carotid artery was dissected and ligated near the carotid bifurcation as previously described.²⁵ Immediately after ligation of the vessel, a group of animals was injected with 0.5 mg of a neutralizing mouse monoclonal antibody against FGF-2 (clone 254F1)⁴¹ that does not cross-react with FGF-1, and additional injections (0.5 mg each) were given 7, 14, and 21 days later. Control animals received equivalent injections of nonimmune mouse IgG at the same time points. All animals were killed 28 days after ligation of the carotid artery. For monitoring antibody levels, serum samples were obtained by retro-orbital bleeds before surgery and once per week for the following 4 weeks. All animals were fixed for 5 minutes by perfusion with 4% paraformaldehyde in 0.1 mol/L sodium phosphate buffer (pH 7.3) as previously described.⁴² The left and right common carotid arteries were embedded in paraffin, and serial sections (5 µm thick) were cut for analysis by morphometry. Ten or more sections spanning the entire length of the vessel within 1 mm of the ligature were analyzed for morphometry. The mean for each animal was calculated.

Blood Pressure and Flow Measurements
Blood pressure was measured in 8-week-old FVB mice anesthetized with ketamine/xylazine with a catheter placed in the femoral artery. Systolic, diastolic, and mean blood pressure were recorded in mice 24 hours after intraperitoneal injection with 0.5 mg of monoclonal antibody 254F1 and in control mice (n=5 mice per group). Flow in the mouse carotid artery was measured near the bifurcation with a 0.5-mm perivascular ultrasonic flow probe connected to a Transonic blood flowmeter.

Morphometry
Morphometric analysis was carried out on the ligated common carotid artery and on the contralateral common carotid artery 4 weeks after ligation. Digitized images of these vessels were analyzed using image analysis software for Apple MacIntosh computers (NIH Image 1.60). The circumference (length) of the lumen, internal elastic lamina (IEL), and external elastic lamina (EEL) were determined by tracing along the luminal surface, IEL, and EEL, respectively. Assuming that the structure was circular, we used these measurements to calculate the lumen area. The medial area was calculated by subtracting the area defined by the IEL from the area defined by the EEL, and intimal area was determined by subtracting lumen area from the area defined by the IEL.

Serum Levels of FGF-2 Antibody
Levels of active FGF-2 antibody in mouse sera were determined by measuring the ability of the sera to inhibit FGF-2 function in a binding assay. Binding of FGF-2 to its high-affinity binding receptor was quantified using a previously published procedure.^{41 43} Briefly, a recombinant fusion protein composed of the 2-loop extracellular portion of FGF receptor-1 (FGFR1) and the heavy chain of mouse IgG2a was captured onto microtiter wells (Immulon 4) coated with IgG2a-specific goat anti-mouse antibody (Southern Biotechnology Inc, Birmingham, Ala). [¹²⁵I]-FGF-2 (3 ng/mL; Biomedical Technologies Inc, Stoughton, Mass) in binding buffer (PBS, 1 mg/mL BSA) was added to the wells and incubated for 90 minutes at 22°C. For inhibition studies, the [¹²⁵I]-FGF-2 was first incubated with serum samples for 30 minutes at 37°C before addition to the receptor. Nonspecific binding was determined as the amount bound in the presence of 1000-fold excess of unlabeled FGF-2. Incubations were terminated by washing the wells 3 times with ice-cold PBS. Bound FGF-2 was measured in a gamma counter.

Statistical Analysis
Student t test was used to compare the means between animals injected with the anti–FGF-2 antibody and the nonimmune IgG (intimal area, lumen area, left carotid medial area, length of IEL, and left carotid EEL). Means were considered significantly different if P0.05. Mann-Whitney U test was used for groups of data that did not have a normal distribution (right carotid medial area and right carotid EEL).

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
We have previously described a mouse model of vascular remodeling in which the left common carotid artery is permanently ligated near the carotid bifurcation. This procedure completely interrupts net flow in this vessel, causing the flow to decrease from 0.58±0.05 mL/min (mean±SEM) in normal vessels to zero in ligated vessels. In the FVB mouse strain, this leads to a decrease in lumen size as a result of neointima formation and inward remodeling of the vessel. In the present study, we determined the role of FGF-2 in the remodeling events by administering a neutralizing murine monoclonal antibody against FGF-2. Levels of antibody were maintained by weekly intraperitoneal injection. Before each injection, a blood sample was obtained and the serum assayed for its ability to inhibit FGF-2 binding in an in vitro binding assay. As shown in Figure 1, antibody levels were maintained throughout the entire experimental period of 4 weeks by weekly injections of 0.5 mg per animal.

View larger version (20K): [in this window] [in a new window]   Figure 1. Serum levels of anti–FGF-2 antibody were determined in mice throughout the 4-week period. The ability of serum to inhibit binding of radiolabeled FGF-2 to its high-affinity receptor was determined in a cell-free assay. Maximum binding was set arbitrarily at 100% and was done in the presence of serum drawn from the mice before antibody injection.

After 4 weeks, the ligated left carotid artery and the contralateral vessel were harvested for morphometric analysis after perfusion fixation. Representative sections of these vessels from the groups of mice treated with anti–FGF-2 antibody and nonimmune IgG are shown in Figure 2. There were no significant differences between groups in medial areas as defined by the IEL and EEL (Table). In comparison to the unmanipulated artery, an approximate 2-fold increase in medial area was seen in the ligated vessels (Table). Measuring intimal areas also revealed no significant difference between groups (Table), and there was no apparent difference in cellularity of the neointima, suggesting that SMC proliferation was not affected by the FGF-2 antibody. Determination of lumen areas, however, revealed striking differences between groups. In the ligated vessels, the lumen was approximately 3-fold larger in the anti–FGF-2–treated animals (Figure 3A). The animals used in the present study had similar body weights. Nevertheless, to account for potential differences in vessel size, we also measured the lumen area of the right carotid artery and determined the ratio of left and right lumen area for each animal. The data revealed that this ratio was 2.4-fold larger in the anti–FGF-2 group (Figure 3C). Interestingly, the unmanipulated carotid arteries of the anti–FGF-2 group also had a significantly larger lumen (Figure 3B). The decrease in lumen area in the ligated vessels is the combined effect of neointima formation as well as inward remodeling of the vessel. To further discriminate between these 2 events, we measured the length of the IEL and the EEL in the ligated and contralateral carotid arteries. The IEL of the left carotid artery was significantly longer in the anti–FGF-2 group (Figure 4A). A small but significant increase in IEL length was also found in the unmanipulated vessel (Figure 4B). The remodeling index (left IEL/right IEL, Figure 4C) was then calculated for each animal, and a significantly larger index was found in the anti–FGF-2 group (0.79±0.02 versus 0.67±0.02 in the control group), indicating that the anti–FGF-2 antibody inhibited negative remodeling. Finally, determination of the EEL length of the unmanipulated carotid artery revealed no significant differences between antibody and control group (Figure 4D and 4E).

View larger version (128K): [in this window] [in a new window]   Figure 2. Representative photomicrographs of cross-sectioned mouse carotid arteries from animals treated with nonimmune IgG (A and B) and anti–FGF-2 antibody (C and D) for 4 weeks. Unmanipulated right carotid artery (A) shows a thin media, whereas remodeling in the ligated carotid artery (B) reveals medial hypertrophy, extensive neointimal lesion formation, and shrinking of the IEL (arrowheads). Treatment with anti–FGF-2 caused dilation of the unmanipulated carotid artery (C) and inhibited lumen narrowing and shrinking of the IEL (arrowheads) in the ligated vessel (D). Blood but no clot formation is found in the lumen. Hematoxylin/eosin stain, original magnification x200.

View this table: [in this window] [in a new window]   Table 1. Medial Area and Neointimal Lesion Formation Are Not Affected by Anti–FGF-2 Treatment After Carotid Artery Ligation

View larger version (17K): [in this window] [in a new window]   Figure 3. Morphometric analysis of lumen areas in the right (unmanipulated) and left (ligated) mouse carotid artery 4 weeks after ligation. Treatment with anti–FGF-2 antibody markedly inhibited lumen narrowing in the ligated arteries (A), but the lumen was also larger in the contralateral carotid artery (B). Lumen area ratios (C) were significantly increased after anti–FGF-2 treatment. Data represent mean±SEM; n indicates number of animals per group.

View larger version (30K): [in this window] [in a new window]   Figure 4. Morphometric analysis of IEL and EEL in the right (unmanipulated) and left (ligated) mouse carotid artery 4 weeks after ligation. Treatment with anti–FGF-2 antibody inhibited shortening of the IEL in the ligated vessels (A), and the IEL of the contralateral vessel (B) was also significantly longer in the anti–FGF-2 group. Remodeling index showed significant inhibition of negative remodeling (C) with anti–FGF-2 antibody treatment. No differences were seen among EEL lengths (D and E). Data represent mean±SEM; n indicates number of animals per group.

Blood pressure was measured in anesthetized control mice and in mice injected with antibody via a catheter placed in the femoral artery. The blood pressure recordings in the FVB mice were low compared with readings reported for other strains of mice; however, there were no significant differences between control and antibody-injected groups in systolic blood pressure (75±2.7 mm Hg and 70±3.5 mm Hg, respectively), diastolic blood pressure (43±3 mm Hg and 43±2.5 mm Hg, respectively), and mean blood pressure (56.8±2.6 mm Hg and 53.2±2.8 mm Hg, respectively).

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
The present study sought to determine the role of FGF-2 in vascular remodeling and intimal lesion formation. We chose to use our previously established model of carotid artery ligation in FVB mice, which is characterized by extensive neointima formation and inward remodeling of the vessel occurring over a period of 4 weeks. Thrombus formation occurs only in the most distal segment of the vessel within 1 to 2 mm of the ligature. This portion of the vessel was excluded from the analysis. Using a mouse monoclonal antibody in the mouse species allowed us to maintain circulating antibody levels for the entire experimental period. The possibility of an immune response that causes antibody to be cleared from circulation was thus markedly reduced. Antibodies from different species are often rapidly eliminated starting in the second week of treatment. In the present study, several interesting observations were made. Consistent with our earlier findings in the rat balloon injury model,³⁹ the intimal lesion formation was not inhibited by the neutralizing anti–FGF-2 antibody, despite the inhibition of early SMC proliferation. Similarly, with use of a rabbit balloon injury model, Parish et al⁴⁴ confirmed that the late-stage neointimal lesion is not inhibited by anti–FGF-2, even though earlier time points showed a reduction in lesion size. In the present study, we did not examine the effects of FGF-2 antibody on early SMC proliferation, and because lesion formation in this model occurs relatively slowly compared with balloon injury models, it will be difficult to detect potential effects on SMC proliferation. The cell density of the neointima as determined by the number of nuclei per unit area was similar between groups, suggesting that cell proliferation may not have been affected by the anti–FGF-2 antibody in this model.

Highly relevant are the recent observations made in the FGF-2–deficient mouse.⁴⁰ These mice formed neointimal lesions in response to vascular injury and vascular tone, as well as blood pressure being reduced.⁴⁰ Administration of the FGF-2 antibody in the present study had dramatic inhibitory effects on inward remodeling, ie, shortening of the IEL and loss of lumen area. These findings are consistent with the concept of FGF-2 as a mediator of vascular tone, although the exact mechanisms by which FGF-2 affects vascular tone still have to be identified.⁴⁰ The contractile apparatus or the coordination of humoral vasoreactive signals are potential targets for FGF-2.⁴⁰ Reduced inward remodeling in the anti–FGF-2–treated mice was not the result of decreased blood pressure that has been described in the FGF-2–deficient mice, given that there was no significant difference in blood pressure between groups in our study. At this time, it is unclear what the source of the FGF-2 might be that regulates vascular tone. Because the ligation model is not a denuding model, it is possible that FGF-2 produced locally in the endothelium or SMCs⁴⁵ might be responsible for these effects in addition to potential levels of circulating FGF-2 found in plasma.

Interesting observations were also made regarding the effect of the anti–FGF-2 antibody on the unmanipulated right carotid arteries. As pointed out earlier, the average body weight of the animals used in the anti–FGF-2 group and the control group was not different, and all animals were perfusion-fixed under physiological pressure. Both the lumen area and the length of the IEL were significantly increased in the unmanipulated carotid artery of the anti–FGF-2 group. These findings can be best explained with the inhibition of vascular tone by the anti–FGF-2 antibody. In summary, the present study identifies FGF-2 as an important factor in vascular remodeling, and its effects are likely to be mediated by increasing vascular tone.

	Acknowledgments

 
Support for this project was provided by the American Heart Association in the form of an Established Investigator Grant awarded to Dr Lindner (9640015N). We would like to thank Christy Munsch for her assistance with the blood pressure measurements.

Received June 3, 1998; accepted November 25, 1998.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 
1. Brownlee RD, Langille BL. Arterial adaptations to altered blood flow. Can J Physiol Pharmacol. 1991;69:978–983.[Medline] [Order article via Infotrieve]

2. Geary RL, Kohler TR, Vergel S, Kirkman TR, Clowes AW. Time course of flow-induced smooth muscle cell proliferation and intimal thickening in endothelialized baboon vascular grafts. Circ Res. 1994;74:14–23.[Abstract/Free Full Text]

3. Kim YH, Chandran CB, Bower TJ, Corson JD. Flow dynamics across end-to-end vascular bypass graft anastomoses. Ann Biomed Eng. 1993;21:311–320.[Medline] [Order article via Infotrieve]

4. Ojha M. Wall shear stress temporal gradient and anastomotic intimal hyperplasia. Circ Res. 1994;74:1227–1231.[Abstract/Free Full Text]

5. Losordo DW, Rosenfield K, Kaufman J, Pieczek A, Isner JM. Focal compensatory enlargement of human arteries in response to progressive atherosclerosis: in vivo documentation using intravascular ultrasound. Circulation. 1994;89:2570–2577.[Abstract/Free Full Text]

6. Kakuta T, Currier JW, Haudenschild CC, Ryan TJ, Faxon DP. Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation. 1994;89:2809–2815.[Abstract/Free Full Text]

7. Lafont AM, Chisolm GM, Whitlow PL, Goormastic M, Cornhill JF. Post-angioplasty restenosis in the atherosclerotic rabbit: proliferative response or chronic constriction? Circulation. 1993;88:I-521. Abstract.

8. Nunes GL, Sgoutas DS, Redden RA, Sigman SR, Gravanis MB. Combination of vitamins C and E alters the response to coronary balloon injury in the pig. Arterioscler Thromb Vasc Biol. 1995;15:156–165.[Abstract/Free Full Text]

9. Mintz GS, Kovach JA, Javier SP, Ditrano CJ, Leon MB. Geometric remodeling is the predominant mechanism of late lumen loss after coronary angioplasty. Circulation. 1993;88:I-654. Abstract.

10. Mintz G, Popma J, Pichard A, Kent K, Satler L. Mechanisms of late arterial responses to transcatheter therapy: a serial quantitative angiographic and intravascular ultrasound study. Circulation. 1994;90:I-24. Abstract.

11. DePaola N, Gimbrone MA Jr, Davies PF, Dewey CF Jr. Vascular endothelium responds to fluid shear stress gradients. Arterioscler Thromb. 1992;12:1254–1257.[Abstract/Free Full Text]

12. Davies PF, Tripathi SC. Mechanical stress mechanisms and the cell: an endothelial paradigm. Circ Res. 1993;72:239–245.[Abstract/Free Full Text]

13. Risau W. Vasculogenesis, angiogenesis and endothelial cell differentiation during embryonic development. Issues Biomed. 1991;14:58–68.

14. Langille BL, O'Donnell F. Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium-dependent. Science. 1986;231:405–407.[Abstract/Free Full Text]

15. Bevan JA, Laher I. Pressure and flow-dependent vascular tone. FASEB J. 1991;5:2267–2273.[Abstract]

16. McLenachan JM, Vita J, Fish RD, Treasure CB, Cox DA, Ganz P, Selwyn AP. Early evidence of endothelial vasodilator dysfunction at coronary branch points. Circulation. 1990;82:1169–1173.[Abstract/Free Full Text]

17. Franke R-P, Grafe M, Schnittler H, Seiffge D, Mittermayer C. Induction of human vascular endothelial stress fibres by fluid shear stress. Nature. 1984;307:648–649.[Medline] [Order article via Infotrieve]

18. Wechezak A, Viggers RF, Sauvage LR. Fibronectin and F-actin redistribution in cultured endothelial cells exposed to shear stress. Lab Invest. 1985;53:639–647.[Medline] [Order article via Infotrieve]

19. Hsieh H-J, Li N-Q, Frangos JA. Shear stress increases endothelial platelet-derived growth factor mRNA levels. Am J Physiol. 1991;260:H642–H646.[Abstract/Free Full Text]

20. Hsieh H-J, Li N-Q, Frangos JA. Shear-induced platelet-derived growth factor gene expression in human endothelial cells is mediated by protein kinase C. J Cell Physiol. 1992;150:552–558.[Medline] [Order article via Infotrieve]

21. Mitsumata M, Fishel RS, Nerem RM, Alexander RW, Berk BC. Fluid shear stress stimulates platelet-derived growth factor expression in endothelial cells. Am J Physiol. 1993;265:H3–H8.[Abstract/Free Full Text]

22. Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol. 1986;250:H1145–H1149.[Abstract/Free Full Text]

23. Guyton JR, Hartley CJ. Flow restriction of one carotid artery in juvenile rats inhibits growth of arterial diameter. Am J Physiol. 1985;248:H540–H546.[Abstract/Free Full Text]

24. Langille BL. Remodeling of developing and mature arteries: endothelium, smooth muscle, and matrix. J Cardiovasc Pharmacol. 1993;21(suppl 1):S11–S17.

25. Kumar A, Lindner V. Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol. 1997;17:2238–2244.[Abstract/Free Full Text]

26. Kumar A, Hoover JL, Simmons CA, Lindner V, Shebuski RJ. Remodeling and neointimal formation in the carotid artery of normal and P-selectin-deficient mice. Circulation. 1997;96:4333–4342.[Abstract/Free Full Text]

27. Tronc F, Wassef M, Esposito B, Henrion D, Glagov S, Tedgui A. Role of NO in flow-induced remodeling of the rabbit common carotid artery. Arterioscler Thromb Vasc Biol. 1996;16:1256–1262.[Abstract/Free Full Text]

28. Xue C, Johns RA. Upregulation of nitric oxide synthase correlates temporally with onset of pulmonary vascular remodeling in the hypoxic rat. Hypertension. 1996;28:743–753.[Abstract/Free Full Text]

29. Mitani Y, Maruyama K, Sakurai M. Prolonged administration of L-arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats [see comments]. Circulation. 1997;96:689–697.[Abstract/Free Full Text]

30. Takemoto M, Egashira K, Tomita H, Usui M, Okamoto H, Kitabatake A, Shimokawa H, Sueishi K, Takeshita A. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension. 1997;30:1621–1627.[Abstract/Free Full Text]

31. Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS, Sessa WC. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest. 1998;101:731–736.[Medline] [Order article via Infotrieve]

32. Fingerle J, Johnson R, Clowes AW, Majesky MW, Reidy MA. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc Natl Acad Sci U S A. 1989;86:8412–8416.[Abstract/Free Full Text]

33. Jackson CL, Raines EW, Ross R, Reidy MA. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterioscler Thromb. 1993;13:1218–1226.[Abstract/Free Full Text]

34. Lindner V, Reidy MA. Platelet-derived growth factor ligand and receptor expression by large vessel endothelium in vivo. Am J Pathol. 1995;146:1488–1497.[Abstract]

35. Ferns GAA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 1991;253:1129–1132.[Abstract/Free Full Text]

36. Mondy JS, Lindner V, Miyashiro JK, Berk BC, Dean RH, Geary RL. Platelet-derived growth factor ligand and receptor expression in response to altered blood flow in vivo. Circ Res. 1997;81:320–327.[Abstract/Free Full Text]

37. Friesel RE, Maciag T. Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J. 1995;9:919–925.[Abstract]

38. Burgess WH, Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem. 1989;58:575–606.[Medline] [Order article via Infotrieve]

39. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci U S A. 1991;88:3739–3743.[Abstract/Free Full Text]

40. Zhou M, Sutliff RL, Paul RJ, Lorenz JN, Hoying JB, Haudenschild CC, Yin M, Coffin JD, Kong L, Kranias EG, Luo W, Boivin GP, Duffy JJ, Pawlowski SA, Doetschman T. Fibroblast growth factor 2 control of vascular tone. Nat Med. 1998;4:201–207.[Medline] [Order article via Infotrieve]

41. Rege AA, Bjercke RJ, Erichsen D, Owens R, Stephan CC, Brock TA. Development of novel monoclonal antibodies for the analysis of functional sites in FGF-2. Growth Factors. In press.

42. Lindner V, Fingerle J, Reidy MA. Mouse model of arterial injury. Circ Res. 1993;73:792–796.[Abstract/Free Full Text]

43. Kan M, Shi E, McKeehan WL. Identification and assay of fibroblast growth factor receptors. Methods Enzymol. 1991;198:158–174.[Medline] [Order article via Infotrieve]

44. Parish MA, Grossi EA, Baumann FG, Asai T, Rifkin DB, Colvin SB, Galloway AC. Effects of a single administration of fibroblast growth factor on vascular wall reaction to injury. Ann Thorac Surg. 1995;59:948–954.[Abstract/Free Full Text]

45. Lindner V, Reidy MA. Expression of basic fibroblast growth factor and its receptor by smooth muscle cells and endothelium in injured rat arteries. An en face study. Circ Res. 1993;73:589–595.[Abstract/Free Full Text]

This article has been cited by other articles:

				J. A.I. Virag, M. L. Rolle, J. Reece, S. Hardouin, E. O. Feigl, and C. E. Murry Fibroblast Growth Factor-2 Regulates Myocardial Infarct Repair: Effects on Cell Proliferation, Scar Contraction, and Ventricular Function Am. J. Pathol., November 1, 2007; 171(5): 1431 - 1440. [Abstract] [Full Text] [PDF]

				Y. Liao, C. P. Regan, I. Manabe, G. K. Owens, K. H. Day, D. N. Damon, and B. R. Duling Smooth Muscle-Targeted Knockout of Connexin43 Enhances Neointimal Formation in Response to Vascular Injury Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1037 - 1042. [Abstract] [Full Text] [PDF]

				T. Raj, P. Kanellakis, G. Pomilio, G. Jennings, A. Bobik, and A. Agrotis Inhibition of Fibroblast Growth Factor Receptor Signaling Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice Arterioscler Thromb Vasc Biol, August 1, 2006; 26(8): 1845 - 1851. [Abstract] [Full Text] [PDF]

				C. K. Sen, S. Khanna, and S. Roy Perceived hyperoxia: Oxygen-induced remodeling of the reoxygenated heart Cardiovasc Res, July 15, 2006; 71(2): 280 - 288. [Abstract] [Full Text] [PDF]

				P. Pyagay, M. Heroult, Q. Wang, W. Lehnert, J. Belden, L. Liaw, R. E. Friesel, and V. Lindner Collagen Triple Helix Repeat Containing 1, a Novel Secreted Protein in Injured and Diseased Arteries, Inhibits Collagen Expression and Promotes Cell Migration Circ. Res., February 4, 2005; 96(2): 261 - 268. [Abstract] [Full Text] [PDF]

				V. Lindner, Q. Wang, B. A. Conley, R. E. Friesel, and C. P.H. Vary Vascular Injury Induces Expression of Periostin: Implications for Vascular Cell Differentiation and Migration Arterioscler Thromb Vasc Biol, January 1, 2005; 25(1): 77 - 83. [Abstract] [Full Text] [PDF]

				B. Kerlin, B. C. Cooley, B. H. Isermann, I. Hernandez, R. Sood, M. Zogg, S. B. Hendrickson, M. W. Mosesson, S. Lord, and H. Weiler Cause-effect relation between hyperfibrinogenemia and vascular disease Blood, March 1, 2004; 103(5): 1728 - 1734. [Abstract] [Full Text] [PDF]

				M. Kuzuya, S. Kanda, T. Sasaki, N. Tamaya-Mori, X. W. Cheng, T. Itoh, S. Itohara, and A. Iguchi Deficiency of Gelatinase A Suppresses Smooth Muscle Cell Invasion and Development of Experimental Intimal Hyperplasia Circulation, September 16, 2003; 108(11): 1375 - 1381. [Abstract] [Full Text] [PDF]

				D. L. Myers, K. J. Harmon, V. Lindner, and L. Liaw Alterations of Arterial Physiology in Osteopontin-Null Mice Arterioscler Thromb Vasc Biol, June 1, 2003; 23(6): 1021 - 1028. [Abstract] [Full Text] [PDF]

				K. A. Detillieux, F. Sheikh, E. Kardami, and P. A. Cattini Biological activities of fibroblast growth factor-2 in the adult myocardium Cardiovasc Res, January 1, 2003; 57(1): 8 - 19. [Abstract] [Full Text] [PDF]

				A. R. Kranenburg, W. I. de Boer, J. H. J.M. van Krieken, W. J. Mooi, J. E. Walters, P. R. Saxena, P. J. Sterk, and H. S. Sharma Enhanced Expression of Fibroblast Growth Factors and Receptor FGFR-1 during Vascular Remodeling in Chronic Obstructive Pulmonary Disease Am. J. Respir. Cell Mol. Biol., November 1, 2002; 27(5): 517 - 525. [Abstract] [Full Text] [PDF]

				J. Shi, G. Perry, M. S. Berridge, G. Aliev, S. L. Siedlak, M. A. Smith, J. C. LaManna, and R. P. Friedland Labeling of Cerebral Amyloid {beta} Deposits In Vivo Using Intranasal Basic Fibroblast Growth Factor and Serum Amyloid P Component in Mice J. Nucl. Med., August 1, 2002; 43(8): 1044 - 1051. [Abstract] [Full Text] [PDF]

				C. J. Sullivan and J. B. Hoying Flow-Dependent Remodeling in the Carotid Artery of Fibroblast Growth Factor-2 Knockout Mice Arterioscler Thromb Vasc Biol, July 1, 2002; 22(7): 1100 - 1105. [Abstract] [Full Text] [PDF]

				B. S. Buetow, J. R. Crosby, W. E. Kaminski, R. K. Ramachandran, P. Lindahl, P. Martin, C. Betsholtz, R. A. Seifert, E. W. Raines, and D. F. Bowen-Pope Platelet-Derived Growth Factor B-Chain of Hematopoietic Origin Is Not Necessary for Granulation Tissue Formation and Its Absence Enhances Vascularization Am. J. Pathol., November 1, 2001; 159(5): 1869 - 1876. [Abstract] [Full Text] [PDF]

				H. Weiler, V. Lindner, B. Kerlin, B. H. Isermann, S. B. Hendrickson, B. C. Cooley, D. A. Meh, M. W. Mosesson, N. W. Shworak, M. J. Post, et al. Characterization of a Mouse Model for Thrombomodulin Deficiency Arterioscler Thromb Vasc Biol, September 1, 2001; 21(9): 1531 - 1537. [Abstract] [Full Text] [PDF]

				J. A. McPherson, K. G. Barringhaus, G. G. Bishop, J. M. Sanders, J. M. Rieger, S. E. Hesselbacher, L. W. Gimple, E. R. Powers, T. Macdonald, G. Sullivan, et al. Adenosine A2A Receptor Stimulation Reduces Inflammation and Neointimal Growth in a Murine Carotid Ligation Model Arterioscler Thromb Vasc Biol, May 1, 2001; 21(5): 791 - 796. [Abstract] [Full Text] [PDF]

				D. Godin, E. Ivan, C. Johnson, R. Magid, and Z. S. Galis Remodeling of Carotid Artery Is Associated With Increased Expression of Matrix Metalloproteinases in Mouse Blood Flow Cessation Model Circulation, December 5, 2000; 102(23): 2861 - 2866. [Abstract] [Full Text] [PDF]

				E. N. T. P. Bakker, E. T. van der Meulen, J. A. E. Spaan, and E. VanBavel Organoid culture of cannulated rat resistance arteries: effect of serum factors on vasoactivity and remodeling Am J Physiol Heart Circ Physiol, April 1, 2000; 278(4): H1233 - H1240. [Abstract] [Full Text] [PDF]

				M. MAYR, C. LI, Y. ZOU, U. HUEMER, Y. HU, and Q. XU Biomechanical stress-induced apoptosis in vein grafts involves p38 mitogen-activated protein kinases FASEB J, February 1, 2000; 14(2): 261 - 270. [Abstract] [Full Text]

				R. Singh, S. Pan, C. S. Mueske, T. Witt, L. S. Kleppe, T. E. Peterson, A. Slobodova, J.-Y. Chang, N. M. Caplice, and R. D. Simari Role for Tissue Factor Pathway in Murine Model of Vascular Remodeling Circ. Res., July 6, 2001; 89(1): 71 - 76. [Abstract] [Full Text] [PDF]

				C. L. Buus, F. Pourageaud, G. E. Fazzi, G. Janssen, M. J. Mulvany, and J. G.R. De Mey Smooth Muscle Cell Changes During Flow-Related Remodeling of Rat Mesenteric Resistance Arteries Circ. Res., July 20, 2001; 89(2): 180 - 186. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bryant, S. R. Articles by Lindner, V. Search for Related Content PubMed PubMed Citation Articles by Bryant, S. R. Articles by Lindner, V. Related Collections Animal models of human disease Growth factors/cytokines Quantitative modeling